

## DAFTAR PUSTAKA

- Adams, L.A., Angulo, P. & Lindor, K.D. 2005. Nonalcoholic fatty liver disease - Adams AL. *CMAJ*, 172(7): 899–905.
- Adinolfi, L.E., Rinaldi, L., Guerrera, B., Restivo, L., Marrone, A., Giordano, M. & Zampino, R. 2016. NAFLD and NASH in HCV infection: Prevalence and significance in hepatic and extrahepatic manifestations. *Int J Mol Sci*, 17(6): 1–12
- Anders, H. & Schaefer, L. 2014. Beyond Tissue Injury — Damage-Associated Molecular Patterns , Toll-Like Receptors , and In fl ammasomes Also Drive Regeneration and Fibrosis. *J Am Soc Nephrol*, 25: 1387–1400.
- Andreasson, U., Perret-Liaudet, A., van Waalwijk van Doorn, L.J.C., Blennow, K., Chiasserini, D., Engelborghs, S., Fladby, T., Genc, S., Kruse, N., Kuiperij, H.B., Kulic, L., Lewczuk, P., Mollenhauer, B., Mroczko, B., Parnetti, L., Vanmechelen, E., Verbeek, M.M., Winblad, B., Zetterberg, H., Koel-Simmelink, M. & Teunissen, C.E. 2015. A practical guide to immunoassay method validation. *Front Neurol*, 6(Aug): 1–8.
- Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwittaya, P., Mills, P.R., Keach, J.C., Lafferty, H.D., Stahler, A., Hafliadottir, S. & Bendtsen, F. 2015. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology*, 149(2): 389-397.e10.
- Aras, Ş., Üstünsoy, S. & Armutçu, F. 2015. Indices of central and peripheral obesity; Anthropometric measurements and laboratory parameters of metabolic syndrome and thyroid function. *Balkan Med J*, 32(4): 414–420.
- Arshad, T., Golabi, P., Paik, J., Mishra, A. & Younossi, Z.M. 2019. Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population. *Hepatol Communications*, 3(1): 74–83.
- Attallah, A.M., Attallah, A.A., Omran, M.M., Rasafy, N., Abdallah, S.O., Shiha, G.E., Farid, K., Nasif, W.A., Abdel-Aziz, A.-A.F. & Shaker, Y.M. 2013. Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients. *Annals of Hepatol*, 12(1): 44–53.
- Aziz-Seible, R.S. & Casey, C.A. 2011. Fibronectin: Functional character and role in alcoholic liver disease. *World J Gastroenterol*, 17(20): 2482–2499.
- Bedossa, P. 2017. Pathology of non-alcoholic fatty liver disease. *Liver Int*, 37: 85–89.
- Bellentani, S. 2010. Epidemiology of Non-Alcoholic Fatty Liver Disease Definition and Classification of Non-Alcoholic Fatty Liver Disease. *Dig Dis*, 28: 155–161. [www.karger.com](http://www.karger.com).
- Bisset, R.A.L.A.N.K. 2002. Differential Diagnosis in Abdominal Ultrasound 2nd edition. : 38–41.
- Buzzetti, E., Pinzani, M. & Tsochatzis, E.A. 2016. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism*, 65(8): 1038–1048.
- Castera, L., Yuen Chan, H.L., Arrese, M., Afdhal, N., Bedossa, P., Friedrich-Rust, M., Han, K.H. & Pinzani, M. 2015. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. *J*

- Hepatol*, 63(1): 237–264.
- Cohen, A.K., Rehkopf, D.H., Deardorff, J. & Abrams, B. 2013. Education and obesity at age 40 among American adults. *Soc Sci Med*, 78(1): 1–7.
- Dowman, J.K., Tomlinson, J.W. & Newsome, P.N. 2009. Pathogenesis of non-alcoholic fatty liver disease. *Q J Med*, (November 2009): 18–21.
- Du, H., Wang, Y., Zhang, Z., Yang, J., Zhang, J. & Zhang, Y. 2015. Fibronectin Overexpression Modulates Formation of Macrophage Foam Cells by Activating SREBP2 Involved in Endoplasmic Reticulum Stress. *Cell Physiol Biochem*, 430030: 1821–1834.
- Elabscience. 2015. Human FN (Fibronectin) ELISA Kit. , 6.
- Fao. 2001. Human energy requirements. *Food Nutr. Bull*, 26(1): 166.
- Golabi, P., Paik, J., Hwang, J.P., Wang, S., Lee, H.M. & Younossi, Z.M. 2019. Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States. *Liver Int*, 39(4): 748–757.
- Gómez-Lechón, M.J. & Castell, J. V. 2009. Measurement of Fibronectin in Human Body Fluids. *Clin Chem Lab Med*, 24(5): 333–339.
- Gondokaryono, S.P., Ushio, H., Niyonsaba, F., Hara, M., Takenaka, H., Jayawardana, S.T.M., Ikeda, S., Okumura, K. & Ogawa, H. 2007. The extra domain A of fibronectin stimulates murine mast cells via Toll-like receptor 4. *J. Leukoc. Biol*, 82(3): 657–665.
- Haglund, C., Ylätupa, S., Mertaniemi, P. & Partanen, P. 1997. Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: A comparison with CA 19-9 and CEA. *Br. J. Cancer*, 76(6): 777–783.
- Hansel, B. 2005. Adipocytokines and insulin resistance. *Annales d'endocrinologie*, 66(2 I): 135–136.
- Harbuwono, D.S., Pramono, L.A., Yunir, E. & Subekti, I. 2018. Obesity and central obesity in indonesia: Evidence from a national health survey. *Med. j. indones*, 27(2): 53–59.
- Hu, K.C., Wang, H.Y., Liu, S.C., Liu, C.C., Hung, C.L., Bair, M.J., Liu, C.J., Wu, M.S. & Shih, S.C. 2014. Nonalcoholic fatty liver disease: Updates in noninvasive diagnosis and correlation with cardiovascular disease. *World J Gastroenterol*, 20(24): 7718–7729.
- Jarnagin, W.R., Rockey, D.C., Koteliensky, V.E., Wang, S.S. & Montgomery Bissell, D. 1994. Expression of variant fibronectins in wound healing: Cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. *Med. J. Cell Biol*, 127(6 II): 2037–2048.
- Jeong, W.K., Lim, H.K., Lee, H.-K., Jo, J.M. & Kim, Y. 2014. Principles and clinical application of ultrasound elastography for diffuse liver disease. *Ultrasonography*, 33(3): 149–160.
- Kementerian Kesehatan Republik Indonesia. 2018. Potret Sehat Indonesia dari Riskesdas 2018. *Kemenkes RI*, (Riskesdas 2013): 2018–2020.
- Kim, D., Kim, W.R., Kim, H.J. & Therneau, T.M. 2013. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. *Hepatology*, 57(4): 1357–1365.
- Kurachi, H., Takahashi, K., Abe, A. & Ohmichi, M. 2005. Women and obesity. *J Am Vet Med Assoc*, 48(1): 42–46.

- Lee, D.H. 2017. Imaging evaluation of non-alcoholic fatty liver disease: Focused on quantification. *Clin Mol Hepatol*, 23(4): 290–301.
- Lee, S.S. & Park, S.H. 2014. Radiologic evaluation of nonalcoholic fatty liver disease. *World J Gastroenterol*, 20(23): 7392–7402.
- Lee, S.S., Park, S.H., Kim, H.J., Kim, S.Y., Kim, M.Y., Kim, D.Y., Suh, D.J., Kim, K.M., Bae, M.H., Lee, J.Y., Lee, S.G. & Yu, E.S. 2010. Non-invasive assessment of hepatic steatosis: Prospective comparison of the accuracy of imaging examinations. *J Hepatol*, 52(4): 579–585.
- Lee, Y.Y. & Wan Muda, W.A.M. 2019. Dietary intakes and obesity of Malaysian adults. *Nutr Res Pract*, 13(2): 159.
- Lefere, S. & Tacke, F. 2019. Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism. *JHEP Reports*, 1(1): 30–43. <https://doi.org/10.1016/j.jhepr.2019.02.004>.
- Lei, H. 2017. ER Stress-Mediated Cell Damage Contributes to the Release of EDA + Fibronectin from Hepatocytes in Nonalcoholic Fatty Liver. *J Huazhong U Sci-Med*, 37(2): 217–225.
- Li, Q., Dhyani, M., Grajo, J.R., Sirlin, C. & Samir, A.E. 2018. Current status of imaging in nonalcoholic fatty liver disease. *Int J Hepatol*, 10(8): 530–542.
- Lim, J.U., Lee, J.H., Kim, J.S., Hwang, Y. Il, Kim, T.H., Lim, S.Y., Yoo, K.H., Jung, K.S., Kim, Y.K. & Rhee, C.K. 2017. Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. *Inter J of COPD*, 12: 2465–2475.
- Liu, X.Y., Liu, R.X., Hou, F., Cui, L.J., Li, C.Y., Chi, C., Yi, E., Wen, Y. & Yin, C.H. 2016. Fibronectin expression is critical for liver fibrogenesis in vivo and in vitro. *Mol Med Rep*, 14(4): 3669–3675.
- Lu, F., Ma, F.F., Zhang, W., Li, Y., Wei, F.Y. & Zhou, L. 2015. Qualitative research of alternatively splice variants of fibronectin in different development stage of mice heart. *J. Thorac. Dis*, 7(12): 2307–2312.
- Maharjan, P., Khanal, P.R., Parajuli, N.P., Joshi, G., Parajuli, H., Khanal, S., Bhatta, B. & Pandeya, D.R. 2017. Biochemical changes in Non-alcoholic fatty liver disease (NAFLD): A study in Nepalese Population. *Anna clin chem lab med CL*, 2(2): 15–20.
- Mcavoy, N.C., Ferguson, J.W., Campbell, I.A.N.W., Hayes, P.C., Ri, P.R.D.I. & Gh, O.A.B. 2006. history , pathogenesis and treatment RE IO ) L ED. *Br J Diabetes Vasc Dis*, 6(6): 1–8.
- Mikolasevic, I., Orlic, L., Franjic, N., Hauser, G., Stimac, D. & Milic, S. 2016. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? *World J Gastroenterol*, 22(32): 7236–7251.
- Moretti, F.A., Chauhan, A.K., Iaconcig, A., Porro, F., Baralle, F.E. & Muro, A.F. 2007. A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived. *J. Biol. Chem*, 282(38): 28057–28062.
- Musso, G., Cassader, M., Olivetti, C., Rosina, F., Carbone, G. & Gambino, R. 2013. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. *Obes Rev*, 14(5): 417–431.

- Musso, G., Gambino, R., Cassader, M. & Pagano, G. 2011. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. *Ann Emerg Med*, 43(8): 617–649.
- Musso, G., Gambino, R., Tabibian, J.H., Ekstedt, M., Kechagias, S., Hamaguchi, M., Hultcrantz, R., Hagström, H., Yoon, S.K., Charatcharoenwitthaya, P., George, J., Barrera, F., Haflidadóttir, S., Björnsson, E.S., Armstrong, M.J., Hopkins, L.J., Gao, X., Francque, S., Verrijken, A., Yilmaz, Y., Lindor, K.D., Charlton, M., Haring, R., Lerch, M.M., Rettig, R., Völzke, H., Ryu, S., Li, G., Wong, L.L., Machado, M., Cortez-Pinto, H., Yasui, K. & Cassader, M. 2014. Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. *PLoS Med*, 11(7).
- Myers, R.P. 2009. Non-Invasive Diagnosis of Nonalcoholic Fatty Liver Disease. *Annals of Hepatology*, 8(1): 23–33.
- Myers, R.P., Pollett, A., Kirsch, R., Pomier-Layrargues, G., Beaton, M., Levstik, M., Duarte-Rojo, A., Wong, D., Crotty, P. & Elakashab, M. 2012. Controlled Attenuation Parameter (CAP): A noninvasive method for the detection of hepatic steatosis based on transient elastography. *Liver Int*, 32(6): 902–910.
- Neuman, M.G., Cohen, L. & Nanau, R. 2014. Biomarkers in nonalcoholic fatty liver disease. *Can J Gastroenterol*, 28(11): 607–618.
- Neuman, M.G., Cohen, L.B. & Nanau, R.M. 2014. Biomarkers in nonalcoholic fatty liver disease. *Can J Gastroenterol*, 28(11): 607–618.
- NICE, G. 2015. Non-alcoholic fatty liver disease. *NICE guideline*, 165(3–4): 147–55; discussion 155–8.
- Nishida, C., Barba, C., Cavalli-Sforza, T., Cutter, J., Deurenberg, P., Darnton-Hill, I., Deurenberg-Yap, M., Gill, T., James, P., Ko, G., Kosulwat, V., Kumanyika, S., Kurpad, A., Mascie-Taylor, N., Moon, H.K., Nakadomo, F., Nishida, C., Noor, M.I., Reddy, K.S., Rush, E., Tunidau Schultz, J., Seidell, J., Stevens, J., Swinburn, B., Tan, K., Weisell, R., Zhao-su, W., Yajnik, C.S., Yoshiike, N. & Zimmet, P. 2004. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *The Lancet*, 363(9403): 157–163.
- Norton, P.A Reis, H.M.G.P.. 2004. Activation of fibronectin gene expression by hepatitis B virus x antigen. *J. Thorac. Dis*, 11(4): 332–341.
- Peng, K., Mo, Z. & Tian, G. 2017. Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males. *Am J Med Sci*, 353(3): 236–241.
- Perumpail, B.J., Khan, M.A., Yoo, E.R., Cholaneril, G., Kim, D. & Ahmed, A. 2017. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. *World J Gastroenterol*, 23(47): 8263–8276.
- Petta, S., Valenti, L., Svegliati-Baroni, G., Ruscica, M., Pipitone, R.M., Dongiovanni, P., Rychlicki, C., Ferri, N., Cammà, C., Fracanzani, A.L., Pierantonelli, I., Di Marco, V., Meroni, M., Giordano, D., Grimaudo, S., Maggioni, M., Cabibi, D., Fargion, S. & Craxì, A. 2017a. Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease. *Journal of Clinical Endocrinology and Metabolism*, 102(8): 2660–2669.

- Petta, S., Valenti, L., Svegliati-Baroni, G., Ruscica, M., Pipitone, R.M., Dongiovanni, P., Rychlicki, C., Ferri, N., Cammà, C., Fracanzani, A.L., Pierantonelli, I., Di Marco, V., Meroni, M., Giordano, D., Grimaudo, S., Maggioni, M., Cabibi, D., Fargion, S. & Craxì, A. 2017b. Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease. *J Clin Endocrinol Metab*, 102(8): 2660–2669.
- Rinella, M. & Charlton, M. 2016. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. *Hepatology*, 64(1): 19–22.
- Rotundo, R.F., Vincent, P.A., McKeown-Longo, P.J., Blumenstock, F.A. & Saba, T.M. 2017. Hepatic fibronectin matrix turnover in rats: involvement of the asialoglycoprotein receptor. *Am J Physiol Gastrointest Liver Physiol*, 277(6): G1189–G1199.
- Schultz, G.S. & Wysocki, A. 2009. Interactions between extracellular matrix and growth factors in wound healing. *Wound Repair Regen*, 17(2): 153–162.
- Sorrentino, P., Terracciano, L., D'Angelo, S., Ferbo, U., Bracigliano, A. & Vecchione, R. 2010. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. *AAm. J. Gastroenterol*, 105(2): 336–344.
- Sporea, I., Popescu, A. & Sirli, R. 2008. Why, who and how should perform liver biopsy in chronic liver diseases. *World J Gastroenterol*, 14(21): 3396–402.
- Strasser, B. 2013. Physical activity in obesity and metabolic syndrome. *Ann N Y Acad Sci*, 1281(1): 141–159.
- Verma, S., Jensen, D., Hart, J. & Mohanty, S.R. 2013. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). *Liver Int*, 33(9): 1398–1405.
- Wang, M. & Kaufman, R.J. 2014. The impact of the endoplasmic reticulum protein-folding environment on cancer development. *Nat. Rev. Cancer*, 14(9): 581–597.
- WHO. 2019. World Health Organization (WHO): Obesity: preventing and managing the global epidemic.
- Yasuda, T. 2006. Cartilage destruction by matrix degradation products. *Mod Rheumatol*, 16(4): 197–205.
- Yoon, J.L., Cho, J.J., Park, K.M., Noh, H.M. & Park, Y.S. 2015. Diagnostic performance of body mass index using the western pacific regional office of world health organization reference standards for body fat percentage. *J Korean Med Sci*, 30(2): 162–166.
- Yoshioka, K., Hashimoto, S. & Kawabe, N. 2015. Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease. *Hepatol Res*, 45(2): 142–151.
- Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. & Wymer, M. 2016. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*, 64(1): 73–84.
- Zhang, Q. & Lu, L. 2015. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. *JCEH*, 3(1): 78–



- 84.
- Sastroasmoro, S., Ismael, S. 2011. *Dasar-Dasar Metodologi Penelitian Klinis*, edisi ke-4. Sagung Seto: Jakarta.
- Salt, W.B. 2004. Nonalcoholic Fatty Liver Disease (NAFLD): A Comprehensive Review. *J Insur Med*, 36: 27-41.
- Schultz, G.S. & Wysocki, A. 2009. Interactions between extracellular matrix and growth factors in wound healing. *Wound Repair Regen*, 17(2): 153–162.
- Sorrentino, P., Terracciano, L., D'Angelo, S., Ferbo, U., Bracigliano, A. & Vecchione, R. 2010. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. *AAm. J. Gastroenterol*, 105(2): 336–344.
- Sporea, I., Popescu, A. & Sirli, R. 2008. Why, who and how should perform liver biopsy in chronic liver diseases. *World J Gastroenterol*, 14(21): 3396–402.
- Strasser, B. 2013. Physical activity in obesity and metabolic syndrome. *Ann N Y Acad Sci*, 1281(1): 141–159.
- Sugondo, S. 2006. *Obesitas*. Sudoyo, A.W., Setiyohadi, B., Alwi, I., Simadibrata, M., Setiati, S. *Metabolik Endokrin*. Edisi ke-4. Departemen Penyakit Dalam Fakultas Kedokteran Universitas Indonesia. Jakarta; 1941 – 1947.
- Verma, S., Jensen, D., Hart, J. & Mohanty, S.R. 2013. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). *Liver Int*, 33(9): 1398–1405.
- Wang, M. & Kaufman, R.J. 2014. The impact of the endoplasmic reticulum protein-folding environment on cancer development. *Nat. Rev. Cancer*, 14(9): 581.
- WHO. 2004. World Health Organization (WHO): *Obesity: preventing and managing the global epidemic*.
- Yasuda, T. 2006. Cartilage destruction by matrix degradation products. *Mod Rheumatol*, 16(4): 197–205.
- Yoon, J.L., Cho, J.J., Park, K.M., Noh, H.M. & Park, Y.S. 2015. Diagnostic performance of body mass index using the western pacific regional office of world health organization reference standards for body fat percentage. *J Korean Med Sci*, 30(2): 162–166.
- Yoshioka, K., Hashimoto, S. & Kawabe, N. 2015. Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease. *Hepatol Res*, 45(2): 142–151.
- Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. & Wymer, M. 2016. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*, 64(1): 73–84.
- Zhang, Q. & Lu, L. 2015. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. *JCEH*, 3(1): 78–84.